세계의 안과용 의약품 및 기기 시장 규모 : 제품 유형별, 용도별, 최종사용자별, 지역별 범위 및 예측

Ophthalmology Drugs And Devices Market Size And Forecast

Ophthalmology Drugs And Devices Market size was valued at USD 57.02 Billion in 2024 and is projected to reach USD 88.18 Billion by 2032, growing at a CAGR of 5.60% from 2024 to 2032.

The increasing prevalence of eye diseases and disorders, rising health awareness among people about the same, presence of a robust pipeline of molecules, and increase in adoption of ophthalmology drugs and devices are driving the growth of the Global Ophthalmology Drugs And Devices Market significantly. The Global Ophthalmology Drugs And Devices Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Ophthalmology Drugs And Devices Market Definition

Ophthalmology is a field of medical science that focuses on the diagnosis and treatment of eye disorders. Ophthalmic devices are used in a variety of procedures such as cataract surgery, glaucoma surgery, and refractive surgery. Ophthalmic drugs are used to treat a wide range of eye diseases, including infection, glaucoma, and cataract. The Global Ophthalmology Drugs And Devices Market is experiencing significant growth because of the rising incidence and prevalence of eye-related disorders such as macular degeneration, presbyopia, and diabetic retinopathy among the geriatric population. With the advent of sophisticated ophthalmic devices, people are increasingly going to opt for ophthalmic surgeries to cure their eye-related disorders.

Global Ophthalmology Drugs And Devices Market Overview

The Global Ophthalmology Drugs And Devices Market is expected to experience remarkable growth in the upcoming years owing to the increasing demand for minimally invasive surgeries in the treatment of various eye-related disorders such as macular degeneration, presbyopia, and diabetic retinopathy among the geriatric population. The increasing incidence and prevalence of eye diseases and disorders, rising health awareness among people about the same, presence of a robust pipeline of molecules, and increase in adoption of ophthalmology drugs and devices in the treatment and diagnosis of certain ocular malformations and eye deficits are fueling the growth of Global Ophthalmology Drugs And Devices Market significantly.

Additionally, technological advancement in the field of Ophthalmology Drugs and Devices and increasing investment in R&D activities for the development of new ophthalmological drugs are also promoting market growth. Furthermore, the rise in the geriatric population across the globe, increasing ophthalmic disorders due to high blood sugar, growth in the healthcare sector, and increasing government initiatives and support in the form of funds and grants for diagnostic equipment and treatment procedures, also boost the growth of the Ophthalmology Drugs And Devices Market.

Moreover, an increase in the patient population of eye-related disorders, increasing product development and launch activities, huge demand for intraocular lenses and phacoemulsification devices, and growth potential in developing nations are expected to provide profitable growth opportunities to the market players in the Global Ophthalmology Drugs And Devices Market during the forecast period. However, high cost associated with the treatment procedures, drug approval delays wherein multiple drugs are in the pipeline, low awareness of ophthalmic drugs, lack of skilled healthcare professionals, and patent expiry is expected to hinder the growth of the Global Ophthalmology Drugs And Devices Market over the forecast period. In addition, risks associated with ocular disease treatment are posing challenges to the growth of the Ophthalmology Drugs And Devices Market.

Global Ophthalmology Drugs And Devices Market Segmentation Analysis

The Global Ophthalmology Drugs And Devices Market is Segmented on the basis of Product Type, Application, End-User, and Geography.

Ophthalmology Drugs And Devices Market, By Product Type

• Anti-allergy
• Anti-Vascular Endothelial Growth Factor (Anti-VEGF) agents
• Anti-inflammatory
• Anti-glaucoma
• Diagnostic and Monitoring Devices
• Surgical Devices
• Vision Care
• Others

Based on Product Type, the market is bifurcated into Anti-allergy, Anti-Vascular Endothelial Growth Factor (Anti-VEGF) agents, Anti-inflammatory, Anti-glaucoma, Diagnostic and Monitoring Devices, Surgical Devices, Vision Care, and Others. The anti-inflammatory segment accounts for the highest revenue share of the Global market in 2020 and is expected to dominate the market over the forecast period owing to an increase in the prevalence of allergic conjunctivitis and hypersensitivity reactions, as well as an increase in demand for anti-inflammatory drugs in a wide range of conditions such as uveitis, cystoid macular edema, and scleritis. These factors are driving the growth of this segment.

Ophthalmology Drugs And Devices Market, By Application

• Dry Eye
• Eye Allergy
• Glaucoma
• Cataract
• Eye Infection
• Retinal Disorders
• Uveitis
• Others

Based on Application, the market is bifurcated into Dry Eye, Eye Allergy, Glaucoma, Cataract, Eye Infection, Retinal Disorders, Uveitis, and Others. The retinal disorders segment is expected to hold the largest revenue share of the global market during the forecast period owing to the rise in the geriatric population, increase in the prevalence of macular degeneration, and an increase in the sale of ophthalmic drugs for the treatment of retinal disorders. However, the glaucoma segment is expected to grow significantly during the forecast period due to an increase in glaucoma prevalence, a rising need for ophthalmic drugs, and an increase in glaucoma prevention and treatment awareness.

Ophthalmology Drugs And Devices Market, By End-User

• Hospitals
• Medical Clinics
• Diagnostic Centers
• Others

Based on End-User, the market is bifurcated into Hospitals, Medical Clinics, Diagnostic Centers, and Others. The hospitals segment is expected to grow at the highest CAGR during the forecast period owing to the increasing number of patients suffering from various eye-related disorders, and rising awareness about these disorders. Additionally, the availability of various diagnostics and treatment facilities, higher purchasing power, and the presence of highly skilled eye care professionals are driving the growth of the global market in the hospitals segment.

Ophthalmology Drugs And Devices Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World
• On the basis of Regional Analysis, The Global Ophthalmology Drugs And Devices Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. Among the regional markets, North America accounts for the largest revenue share in the Global Ophthalmology Drugs And Devices Market in 2020 and is expected to retain its dominance throughout the forecast period. The revenue growth in the North American market is mainly attributed to the increased investment in R&D activities for the development of technologically advanced medical devices and innovative drugs for the treatment of various eye-related disorders.
• Additionally, the increasing geriatric population, rising incidence and prevalence of various eye-related disorders, rising healthcare sectors, presence of skilled eye care professionals, and wide availability of technologically advanced ophthalmology devices are the major factors that boost the Ophthalmology Drugs And Devices Market growth across the region. The market in the Asia Pacific is projected to witness expansion at a significant growth rate during the forecast period, owing to the increasing focus on the development of healthcare infrastructure and the rising prevalence of various eye-related disorders such as glaucoma and cataract in developing nations such as China, and India in this region.

Key Players

The "Global Ophthalmology Drugs And Devices Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Carl Zeiss AG, Novartis AG, Johnson And Johnson Services, Inc., Allergan, Topcon Corporation, Nidek Co., Ltd., HAAG-STREIT GROUP, Ziemer Ophthalmic Systems, Bausch And Lomb Incorporated, Biotech, VisionCare, Inc., Akorn, Incorporated, Bayer AG, Acucela Inc., Regeneron Pharmaceuticals, Inc, Nicox, Santen Pharmaceutical Co., Ltd. and IRIDEX Corporation, Alcon Inc. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• In August 2020, Topcon Corporation purchased the Henson line of perimetry products, including the Henson 9000 and 7000, from the United Kingdom-based Elektron Eye Technology (EET) of Cambridge.
• In January 2020, iCare's IC200 tonometer device was approved by the US FDA.
• In March 2019, Alcon Inc. acquired Power Vision Inc., a privately held medical device development company based in the United States that specializes in fluid-based intraocular lens implants.
• In August 2018, CEQUA, developed by Sun Pharmaceutical Industries Ltd., had been approved by the US FDA for the treatment of dry eye diseases.
• In July 2018, Amring Pharmaceuticals, Inc. introduced Biolon ophthalmic viscosurgical devices for cataract surgeons in the United States.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL OPHTHALMOLOGY DRUGS AND DEVICES MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL OPHTHALMOLOGY DRUGS AND DEVICES MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL OPHTHALMOLOGY DRUGS AND DEVICES MARKET, BY PRODUCT TYPE

• 5.1 Overview
• 5.2 Anti-allergy
• 5.3 Anti-Vascular Endothelial Growth Factor (Anti-VEGF) agents
• 5.4 Anti-inflammatory
• 5.5 Anti-glaucoma
• 5.6 Diagnostic and Monitoring Devices
• 5.7 Surgical Devices
• 5.8 Vision Care
• 5.9 Others

6 GLOBAL OPHTHALMOLOGY DRUGS AND DEVICES MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Dry Eye
• 6.3 Eye Allergy
• 6.4 Glaucoma
• 6.5 Cataract
• 6.6 Eye Infection
• 6.7 Retinal Disorders
• 6.8 Uveitis
• 6.9 Others

7 GLOBAL OPHTHALMOLOGY DRUGS AND DEVICES MARKET, BY END-USER

• 7.1 Overview
• 7.2 Hospitals
• 7.3 Medical Clinics
• 7.4 Diagnostic Centers
• 7.5 Others

8 GLOBAL OPHTHALMOLOGY DRUGS AND DEVICES MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Middle East and Africa
  • 8.5.2 Latin America

9 GLOBAL OPHTHALMOLOGY DRUGS AND DEVICES MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Carl Zeiss AG
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Novartis AG
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Johnson And Johnson Services, Inc.
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Allergan
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Topcon Corporation
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Nidek Co., Ltd.
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 HAAG-STREIT GROUP
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Ziemer Ophthalmic Systems
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Bausch And Lomb Incorporated, Biotech
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 9.10 VisionCare, Inc.
  • 9.10.1 Overview
  • 9.10.2 Financial Performance
  • 9.10.3 Product Outlook
  • 9.10.4 Key Developments
• 9.11 Akorn
  • 9.11.1 Overview
  • 9.11.2 Financial Performance
  • 9.11.3 Product Outlook
  • 9.11.4 Key Developments
• 9.12 Incorporated
  • 9.12.1 Overview
  • 9.12.2 Financial Performance
  • 9.12.3 Product Outlook
  • 9.12.4 Key Developments
• 9.13 Bayer AG
  • 9.13.1 Overview
  • 9.13.2 Financial Performance
  • 9.13.3 Product Outlook
  • 9.13.4 Key Developments
• 9.14 Acucela Inc.
  • 9.14.1 Overview
  • 9.14.2 Financial Performance
  • 9.14.3 Product Outlook
  • 9.14.4 Key Developments
• 9.15 Regeneron Pharmaceuticals, Inc
  • 9.15.1 Overview
  • 9.15.2 Financial Performance
  • 9.15.3 Product Outlook
  • 9.15.4 Key Developments
• 9.16 Nicox
  • 9.16.1 Overview
  • 9.16.2 Financial Performance
  • 9.16.3 Product Outlook
  • 9.16.4 Key Developments
• 9.17 Santen Pharmaceutical Co., Ltd
  • 9.17.1 Overview
  • 9.17.2 Financial Performance
  • 9.17.3 Product Outlook
  • 9.17.4 Key Developments
• 9.18 IRIDEX Corporation
  • 9.18.1 Overview
  • 9.18.2 Financial Performance
  • 9.18.3 Product Outlook
  • 9.18.4 Key Developments
• 9.19 Alcon Inc
  • 9.19.1 Overview
  • 9.19.2 Financial Performance
  • 9.19.3 Product Outlook
  • 9.19.4 Key Developments

11 Appendix

• 11.1.1 Related Reports